Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Trial finds improvement in control and weight loss.
Read More »EASD: SGLT-2/GLP-1 Combo Better Than Monotherapy
Effects of SGLT-2 Inhibitors On UTIs and Genital Infections
Lowering HbA1c worth the risk of urinary tract and genital infections?
Read More »Even More Protection for the Kidneys With An SGLT-2 Inhibitor (And a comment from George Bakris, MD)
New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of empagliflozin in patients with type 2 and cardiovascular disease.
Read More »George Bakris Part 2, SGLT-2 Inhibitors and the Diabetic Kidney
Dr. George Bakris talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about the possible kidney benefits for those using SGLT-2s.
Read More »Jaime Davidson Transcript
Dr. Davidson discusses new diabetes drugs and their impact on patient health, including DKA; new combination drugs; and the expensive side effects of sulfonylureas.
Read More »Dr. Jaime Davidson Full Interview
In this Exclusive Interview, Dr. Davidson discusses his thoughts on new drugs and their impact on patient health, such as DKA.
Read More »Use of SGLT-2 inhibitors As Adjunct to Insulin In People with Type 1 Diabetes
Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.
Read More »ADA: Canagliflozin Reduces Risk of Cardiovascular Disease, Hospitalization for Heart Failure; Associated with Renal Protective Effects
CANVAS Program results confirm cardiovascular benefits are SGLT-2 Inhibitor Class effect.
Read More »Exclusive: Dr Bruce Neal Discusses Canagliflozin’s Potential for Heart Failure Prevention
Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have an exclusive interview from ADA 2017. The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Dr. Bruce Neal.
Read More »Bruce Neal ADA 2017 Pt.1, CANVAS Program and Cardiovascular Event Reduction
Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 1 of this ...
Read More »